O’Leary on Mind Medicine: O’Leary told Benzinga the psychedelics industry remains attractive with trials for treating mental health problems. With no new treatment options in years, the opportunity for the industry looks promising.
O’Leary said there is a “massive, massive problem” that a company like Mind Medicine can help tackle.
The CEO of Mind Medicine approached O’Leary when looking for early-round investors to put capital to work.
“We became major investors,” O’Leary told Benzinga.
Mind Medicine has hit every milestone the CEO told O’Leary it would hit, he said. The company is working on FDA approval in the future and could also be uplisted to a major exchange like the Nasdaq.
“I see no reason why Nasdaq wouldn’t be interested in this sector,” O’Leary said, adding that he thinks the Nasdaq maintains an entrepreneurial spirit.
O’Leary told Benzinga he believes Mind Medicine is still “in its third inning.”
Investing in Psychedelics: O’Leary offered up advice for investors looking for exposure to the psychedelics industry.
“The outcomes are unknown, highly speculative,” O’Leary said on the psychedelics space.
O’Leary said investors should consider diversifying their risk and finding companies that are doing multiple trials, like Mind Medicine.
Investing in companies in the space that have only one trial risk potentially becoming worthless if the treatment is not approved.
“No. 1 for me is MindMed," O’Leary said.
Price Target: Shares of Mind Medicine were up 2% to $2.79 on Friday. Shares are up around 1200% in the last 52 weeks.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.